Chronus Health raises $ 22 million for a fast, portable blood tester


What you should know:

Chronus Health, a diagnostic company at the spotlight raises $ 22 million in Series A funding led by Tarsadia Investments with the participation of Mount Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor.

– Chronus intends to use the proceeds from Series A funding to scale its research, engineering and data science teams, as well as accelerate the company’s product and technology development.

Diagnosis on demand. Reimagined

While many vital signs are easily obtained, the only test that doctors rely on to make 70% of their diagnoses, the blood test, can take days to get results. Existing blood analyzers are expensive, bulky, perform limited testing, and require a trained lab technician to function. As a result, the only option has been to send blood samples to a central laboratory for analysis, introducing delays that can negatively affect patient care. Chronus Health’s portable in vitro diagnostic (IVD) platform facilitates real-time blood diagnosis at the point of care, providing lab results in minutes with the goal of dramatically improving patient outcomes. The system is designed to handle approximately 85% of the blood tests performed annually.

The Chronus Health system is designed to provide real-time blood test results to healthcare providers, providing them with immediate action data. By leveraging microfluidics and semiconductor technology combined with powerful analytics using data science tools, we are redefining what is possible in point-of-care blood tests.

“Our groundbreaking platform is poised to disrupt the clinical lab testing market, which relies primarily on expensive, bulky blood analyzers in central labs,” explains Anand Parikh, CEO and co-founder of Chronus Health. “Our compact, low-cost system, which leverages microfluidic and semiconductor technologies, enables real-time diagnostics in multiple clinical settings and is designed to improve patient care time and outcomes worldwide.”

Source link